Davidson Mattinsider trades
In SEC Form 4 filings, Davidson Matt is listed as President and CEO of Adial Pharmaceuticals, Inc. (ADIL). Davidson Matt reported no open-market purchases or sales in the last 90 days. The latest Form 4 transaction on record was filed on Oct 30.
Companies and roles
| Company | Role | Transactions | Last filed |
|---|---|---|---|
| ADILAdial Pharmaceuticals, Inc. | President and CEO | 7 | Oct 30 |
Cluster buys
No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).
Form 4 historysince 2026-10-30
| Company | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| ADILAdial Pharmaceuticals, Inc. | Oct 28 | Oct 30 | A | 232,417 | $0.00 | $0 | 294,064 | No | Form 4 |
| ADILAdial Pharmaceuticals, Inc. | Oct 28 | Oct 30 | A · derivative | 1,822.13 | not reported | not reported | 1,822.13 | No | Form 4 |
| ADILAdial Pharmaceuticals, Inc. | Oct 28 | Oct 30 | A · derivative | 101.3 | not reported | not reported | 101.3 | No | Form 4 |
| ADILAdial Pharmaceuticals, Inc. | Oct 28 | Oct 30 | A · derivative | 232,417 | $2.98 | $692,603 | 232,417 | No | Form 4 |
| ADILAdial Pharmaceuticals, Inc. | Oct 28 | Oct 30 | A · derivative | 286,044 | $0.54 | $154,464 | 286,044 | No | Form 4 |
| ADILAdial Pharmaceuticals, Inc. | Oct 28 | Oct 30 | A · derivative | 31,914 | $1.57 | $50,105 | 31,914 | No | Form 4 |
| ADILAdial Pharmaceuticals, Inc. | Oct 28 | Oct 30 | A · derivative | 333,830 | $0.63 | $210,313 | 333,830 | No | Form 4 |
Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.